The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.
المخرجات
Research outputs
Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.
International Journal of Community Medicine and Public Health · vol. 9 (2) · 1068-1068
Many complications were reported secondary to herniation, including strangulation and incarceration, leading to intestinal obstruction and related clinical manifestations. Treating such cases is largely dependent on appropriately diagnosing and evaluating them to enhance the prognosis and prevent a recurrence. In the present literature review, we have discussed incarcerated hernias' clinical and radiological features. Physical examination is very important in establishing the diagnosis of these events and obtaining a thorough history from the patient. Most patients present with abdominal pain, tenderness, and erythematous changes. Signs of intestinal obstruction might also be reported when this complication develops. Signs include acute abdominal pain, nausea, and vomiting. Radiological findings might show the presence of air to fluid appearance. Clinicians should be aware of these clinical manifestations and perform an adequate physical examination to establish a proper diagnosis and manage these cases. The process of decision-making is important before deciding the most appropriate management approach. Therefore, it is important to assess patients before moving to the next steps.
Indian Journal of Pharmaceutical Education and Research · vol. 56 (1) · 17-23
Background: The value of scientific research should be instilled in students from the very beginning of their university education, to foster a creative attitude in the next generation.It is critical to promote a research culture using various technologies and strategies.Purpose: The purpose of this study was to assess students' perspectives towards scientific research and to learn more about the obstacles they confront in this area.Methods: Students at the Colleges of Medicine (COM), Pharmacy (COP), and Applied Sciences (CAS) were given a validated, pretested, and organized questionnaire (COA).Using the SPSS IBM 23 application, the data was examined utilizing descriptive statistics.Also, correlation statistics was done to determine the influence of perception, obstacles, and practices on each other.The statistical significance level was set at P#0.05.Results: When compared to their COA counterparts (3.8/5), COM (4.3/5) and COP (4.2/5) students had considerably higher average perception scores on the Likert response scale.The most significant barriers to undertaking research were a lack of time and research training.Both male and female students had a positive perception towards research.Female students, on the other hand, were more likely to engage in the practice.Positive correlation was noticed between perception and practice of scientific research.Higher level of obstacles influenced negatively on the practices of research among most of the University students.Conclusion: Although, college of Pharmacy and college of medicine students participate more regularly in scientific research, there is a need to orient them on the dissemination of their research outcomes.To foster a research environment and improve research practices among students, authorities and faculty members at AlMaarefa University should address and resolve these challenges.
pharmacy studentsstudent perceptions of researchbarriers to researchresearch culture
Perivascular epithelioid cell tumors (PEComas) are infrequent mesenchymal neoplasms. Primary uterine PEComas are extremely uncommon. To the best of knowledge, around 110 cases of uterine PEComas have been documented in the English-language literature thus far. Herein, we present the case of primary uterine PEComa in a 56-year-old Saudi woman who presented to clinical attention with a six-month history of left-sided abdominal pain. Gynecological examination showed a 5-cm solid mass involving the left adnexa. Tumor markers were normal. Computed tomography scan demonstrated a 4.2 x 4.4 x 3.4 cm superior left fundal exophytic mass. Patient underwent total abdominal hysterectomy plus bilateral salpingo-oophorectomy. Final histopathological examination demonstrated benign/uncertain malignant potential PEComa. No further adjuvant therapy was administered. At six-month follow up, the patient was asymptomatic without recurrence. In conclusion, uterine PEComas are rare. Histopathological assessment establishes the definitive diagnosis. Surgery remains the gold standard in the treatment of uterine PEComas and adjuvant therapy should be guided based on clinical and histopathological risk factors. Keywords: Uterine perivascular epithelioid cell tumor; PEComa; Uterine sarcoma; hysterectomy.
Saudi Journal of Otorhinolaryngology Head and Neck Surgery · vol. 24 (1) · 17-21
Background: Basal cell carcinoma (BCC) is the most frequent malignant tumor in dermatology. The burden of advanced BCC is not fully understood and was not well studied in Sudan. Objective: The objectives of this work were to study the BCC disease characteristics, burden, and morbidity on a group of Sudanese patients. Patients and Methods: This is a retrospective, hospital-based study of patients' records presented to the Military Dermatology Hospital and diagnosed with BCC. The study period was 2012–2017. Results: Our team identified a total number of 27 patients to have BCC. 15 (55.6%) were males and 12 (44.4%) were females. The mean age was 54 years (with a range of 26–75 years). The site of the location of the lesions was mostly the face in 22 (81.5%), face and extremities in 4 (14.8%) patients, and in only one (3.7%) patient, it was on the abdomen. The face distribution includes the forehead (14.5%), periocular (18.5%), nose (18.5%), nose, mouth, and cheek (7.4%). The clinical presentation of the lesions includes pigmentation (70.4%), ulcers (63%), plaques (55.6%), nodules (40.7%), scars (11.1%), and deformity associated with advanced BCC in (48.2%) of the patients. The associated comorbidities were (11.1%), albinism (11.1%), and basal cell nevus syndrome (BCNS) (3.7%). Concerning the outcome and prognosis, 11 (40.7%) had a good prognosis and 16 (59.3%) had a bad prognosis. Conclusions: BCC has similar epidemiological and clinical presentation as many international studies with younger age incidence. Delay presentation results in local disease advancement and increases severity and burden. This bad burden could be attributed to inadequate health facilities.
basal cell carcinomadisease burdenSudanese patientsclinical features
Journal of Healthcare Sciences · vol. 02 (04) · 46-51
Stroke, also known as a cerebrovascular accident, is a medical emergency characterized by an immediate disruption of cerebral perfusion or vasculature. Strokes are divided into two categories: ischemic stroke and haemorrhagic stroke. Strokes can be caused by a variety of factors, including high blood pressure, arteriosclerosis, and emboli generated in the heart as a consequence of atrial fibrillation or rheumatic heart disease. Stroke is linked to a number of risk factors, that are categorized into modifiable and non-modifiable risk factors. In order to reduce stroke-related morbidity and mortality, prevention is critical. It is believed that 50% of strokes can be avoided by controlling modifiable risk factors and making lifestyle modifications. The purpose of this research is to review the available information regarding screening, risk factors and prevention of stroke. Hypertension, smoking, obesity, diet, lack of physical activity, diabetes mellitus, alcohol consumption, mental distress, heart disease, and lipid disorders account for 90% of strokes, depending on the number of risk factors included. Medical interventions that have been demonstrated in numerous randomized trials can significantly lower the risk of stroke. Observational research clearly suggests that healthy eating habits, quitting smoking and abstaining from excessive alcohol consumption, regular physical activity, and maintaining a normal body weight are all helpful for stroke prevention. In order to facilitate services for preventative stroke treatments and acute stroke care, community awareness of stroke risk factors and symptoms must be improved. Education, awareness as well as screening for risk factors of stroke among public is need of time.
Journal of Healthcare Sciences · vol. 02 (11) · 478-483
The normal course of Chronic obstructive pulmonary disease (COPD) includes a progressive reduction in lung function, exacerbations that necessitate primary care intervention or hospital admission, a steady decline in quality of life, and a shorter life expectancy. COPD is one of the ambulatory or primary care-sensitive illnesses for which it is hypothesized that efficient primary care management will lower the probability of hospital admission. Long-acting beta-agonist and inhaler steroid combination therapy improves spirometric results and overall health while lowering the annual risk of COPD exacerbations. Use of two or more treatment modules based on models designed specifically for chronic care delivery in developed countries have proven successful in lowering hospitalizations as well. Access to other therapies, such as pulmonary rehabilitation, acute exacerbation evaluation programs, and community or hospital-based respiratory specialists, may also be important. The goal of interventions to lessen the prevalence of COPD in underserved areas has to focus on locally driven integrated solutions, such as media campaigns to raise awareness and persuade at-risk individuals to get tested, as well as training for primary care workers on the significance and advantages of earlier detection and effective operation of chronic obstructive pulmonary disease. Importantly, uptake of influenza vaccination has demonstrated a link with hospital admission rates at the practice level. Proposed solutions for lowering hospitalization and reducing exacerbations among patients with COPD include greater access to pulmonary rehabilitative care, more rigorous implementation of smoking cessation programs and availability of modern long-acting medications.
International Journal of Morphology · vol. 40 (5) · 1300-1307
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent a unique class of glucose-declining renal-targeted drugs.The SGLT2i Canagliflozin (CANA) is an anti-hyperglycemic drug that reduces various cardiovascular and renal outcomes in patients with type 2 diabetes mellitus.This study aimed to explore the potential effects of CANA on the isolated healthy adult rat hearts to show if CANA has positive inotropic or cardiac depressant effects via analyzing the amplitude and frequency of cardiac contractions.In isolated normal adult rat hearts, the effects of CANA on cardiac contractility were examined.In a dose-response curve, CANA led to a significant cardiac depressant effect in a dose-dependent manner.This cardiac depressant effect of CANA (10 -6 M) was not prevented by atropine.However, this cardiac depressant effect was partially antagonized by both Isoproterenol (10 -5 M) and Calcium chloride (10 -6 M), suggesting beta-adrenoceptor and calcium channel blocking actions.In addition, the cardiac depressant effect of CANA (10 -6 M) was mitigated in part by Nitric oxide synthase inhibitor, L-NAME, suggesting that its action probably depends to some extent on the accumulation of nitric oxide, which decreases the rise of intracellular Calcium.Data from this study demonstrate that CANA has a significant cardiac relaxant effect in isolated hearts of healthy adult rats by different possible mechanisms.This inhibitory effect on cardiac contractility may help improve the diastolic ventricular filling providing a therapeutic potential to help the other cardioprotective mechanisms of CANA in the prevention and treatment of heart failure.
World Journal of Environmental Biosciences · vol. 11 (3) · 45-49
A frequent illness, pulmonary embolism can cause considerable morbidity and mortality. Certain inherited and acquired risk factors predispose vulnerable individuals, and the clinical situation can arouse suspicion. Studies involving people who had non-alcoholic fatty liver disease were sought after in the Medline, Pubmed, Embase, NCBI, and Cochrane databases. Analysis was done on incidence, etiology, and treatment options. Because PE presents differently in each patient, it is important to take
Clinical Cancer Investigation Journal · vol. 11 (2) · 32-35
The current review is about Colorectal Cancer (CRC) which is the third most prevalent malignancy and the fourth most frequent cause of cancer-related death. However, only 1% to 4% of incidences are documented in people between the ages of 25 and 30. A family history of colon or rectal cancer, diet, alcohol consumption, smoking, and inflammatory bowel disease are some risk factors for Colorectal Cancer. Various database including the Medline, Pubmed, Embase, NCBI, and Cochrane databases were sear
Annals of Pharmacy Practice and Pharmacotherapy · vol. 2 (1) · 39-50
During severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the chance of suffering acute kidney injury (AKI) increases significantly. Therefore, the present study aimed to conduct a comprehensive pharmacotherapeutic evaluation of AKI in patients with coronavirus. From July to August 2021, a retrospective cohort study was conducted on coronavirus patients hospitalized at the Institute of Kidney Diseases, Hayatabad Medical Complex in Peshawar, Pakistan. Demographics, diagnosis,
The rapid and global spread of a new human coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has produced an immediate urgency to discover promising targets for the treatment of COVID-19. Here, we consider drug repurposing as an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications. We review current information concerning the global health issue of COVID-19 including promising approved drugs, e.g., human angiotensin-converting enzyme inhibitors (hACEIs). Besides, we describe computational approaches to be used in drug repurposing and highlight examples of in-silico studies of drug development efforts against SARS-CoV-2. Alacepril and lisinopril were found to interact with human angiotensin-converting enzyme 2 (hACE2), the host entranceway for SARS-CoV-2 spike protein, through exhibiting the most acceptable rmsd_refine values and the best binding affinity through forming a strong hydrogen bond with Asn90, which is assumed to be essential for the activity, as well as significant extra interactions with other receptor-binding residues. Furthermore, molecular dynamics (MD) simulations followed by calculation of the binding free energy were also carried out for the most promising two ligand-pocket complexes from docking studies (alacepril and lisinopril) to clarify some information on their thermodynamic and dynamic properties and confirm the docking results as well. These results we obtained probably provided an excellent lead candidate for the development of therapeutic drugs against COVID-19. Eventually, animal experiments and accurate clinical trials are needed to confirm the potential preventive and treatment effect of these compounds.
The emergence of infectious diseases promises to be one of the leading mortality factors in the healthcare sector. Although several drugs are available on the market, newly found microorganisms carrying multidrug resistance (MDR) against which existing drugs cannot function effectively, giving rise to escalated antibiotic dosage therapies and the need to develop novel drugs, which require time, money, and manpower. Thus, the exploitation of antimicrobials has led to the production of MDR bacteria, and their prevalence and growth are a major concern. Novel approaches to prevent antimicrobial drug resistance are in practice. Nanotechnology-based innovation provides physicians and patients the opportunity to overcome the crisis of drug resistance. Nanoparticles have promising potential in the healthcare sector. Recently, nanoparticles have been designed to address pathogenic microorganisms. A multitude of processes that can vary with various traits, including size, morphology, electrical charge, and surface coatings, allow researchers to develop novel composite antimicrobial substances for use in different applications performing antimicrobial activities. The antimicrobial activity of inorganic and carbon-based nanoparticles can be applied to various research, medical, and industrial uses in the future and offer a solution to the crisis of antimicrobial resistance to traditional approaches. Metal-based nanoparticles have also been extensively studied for many biomedical applications. In addition to reduced size and selectivity for bacteria, metal-based nanoparticles have proven effective against pathogens listed as a priority, according to the World Health Organization (WHO). Moreover, antimicrobial studies of nanoparticles were carried out not only in vitro but in vivo as well in order to investigate their efficacy. In addition, nanomaterials provide numerous opportunities for infection prevention, diagnosis, treatment, and biofilm control. This study emphasizes the antimicrobial effects of nanoparticles and contrasts nanoparticles' with antibiotics' role in the fight against pathogenic microorganisms. Future prospects revolve around developing new strategies and products to prevent, control, and treat microbial infections in humans and other animals, including viral infections seen in the current pandemic scenarios.
The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir, an orally active RdRp inhibitor, is in a phase 3 clinical trial against COVID-19. The objective of this review article is to enlighten the researchers working on COVID-19 about the discovery, recent developments, and patents related to molnupiravir. Molnupiravir was originally developed for the treatment of influenza at Emory University, USA. However, this drug has also demonstrated activity against a variety of viruses, including SARS-CoV-2. Now it is being jointly developed by Emory University, Ridgeback Biotherapeutics, and Merck to treat COVID-19. The published clinical data indicate a good safety profile, tolerability, and oral bioavailability of molnupiravir in humans. The patient-compliant oral dosage form of molnupiravir may hit the market in the first or second quarter of 2022. The patent data of molnupiravir revealed its granted compound patent and process-related patent applications. We also anticipate patent filing related to oral dosage forms, inhalers, and a combination of molnupiravir with marketed drugs like remdesivir, favipiravir, and baricitinib. The current pandemic demands a patient compliant, safe, tolerable, and orally effective COVID-19 treatment. The authors believe that molnupiravir meets these requirements and is a breakthrough COVID-19 treatment.
Cancer is a group of disorders characterized by uncontrolled cell growth that affects around 11 million people each year globally. Nanocarrier-based systems are extensively used in cancer imaging, diagnostics as well as therapeutics; owing to their promising features and potential to augment therapeutic efficacy. The focal point of research remains to develop new-fangled smart nanocarriers that can selectively respond to cancer-specific conditions and deliver medications to target cells efficiently. Nanocarriers deliver loaded therapeutic cargos to the tumour site either in a passive or active mode, with the least drug elimination from the drug delivery systems. This review chiefly focuses on current advances allied to smart nanocarriers such as dendrimers, liposomes, mesoporous silica nanoparticles, quantum dots, micelles, superparamagnetic iron-oxide nanoparticles, gold nanoparticles and carbon nanotubes, to list a few. Exhaustive discussion on crucial topics like drug targeting, surface decorated smart-nanocarriers and stimuli-responsive cancer nanotherapeutics responding to temperature, enzyme, pH and redox stimuli have been covered.
smart nanocarrierscancer nanotherapeuticsstimuli-responsive drug deliverytargeted drug delivery